News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at email@example.com
December 08, 2022COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
December 01, 2022Pursuing passions: on playing Horseball for Great Britain
Our R&D Assistant, Maya Carter-Birch, tells us how she balances playing Horseball internationally with her work at COMPASS and her social life.
November 09, 2022Celebrating World Quality Week at COMPASS
This week we're recognising and celebrating World Quality Week.
November 03, 2022COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine